Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

BACKGROUND: The National Cancer Institute—Molecular Analysis for Therapy Choice (NCI-MATCH) is a national precision medicine study incorporating centralized genomic testing to direct refractory cancer patients to molecularly targeted treatment subprotocols. This treatment subprotocol was designed to...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Ann Oncol
Main Authors: Jhaveri, K L, Wang, X V, Makker, V, Luoh, S -W, Mitchell, E P, Zwiebel, J A, Sharon, E, Gray, R J, Li, S, McShane, L M, Rubinstein, L V, Patton, D, Williams, P M, Hamilton, S R, Conley, B A, Arteaga, C L, Harris, L N, O’Dwyer, P J, Chen, A P, Flaherty, K T
Formato: Artigo
Idioma:Inglês
Publicado: Oxford University Press 2019
Assuntos:
Original Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6927318/
https://ncbi.nlm.nih.gov/pubmed/31504139
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz291
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares